On July 7, Unilever rose 3.03% in regular trading, reaching $63.435 per share with turnover of approximately $39.04 million. The movement was driven by renewed market attention on reports that Unilever is evaluating a potential bid for Thorne, a South Carolina-based dietary supplements manufacturer, in a deal valued at up to $4 billion.

Thorne has been put up for sale by its private equity owner L Catterton, with several other companies also exploring a potential acquisition. Neither Unilever, Thorne, nor L Catterton have publicly commented on the matter. The potential acquisition aligns with Unilever's accelerating pivot toward health and personal care. The company completed its acquisition of supplements brand Gruns earlier this year and finalized the divestiture of its food business to McCormick in a transaction valuing the food unit at roughly $44.8 billion, allowing Unilever to concentrate on higher-margin growth categories in beauty, wellbeing, and personal care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)